4D Molecular Therapeutics Inc (FDMT)

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is a clinical-stage biotherapeutics company that specializes in developing genetic medicines through its innovative therapeutic vector evolution platform.

The company's genetic medicine product portfolio primarily focuses on ophthalmology, cardiology, and pulmonology. It has various product candidates in clinical trials, including 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease cardiomyopathy.

Furthermore, 4D Molecular Therapeutics is also working on products like 4D-150 for wet age-related macular degeneration and diabetic macular edema, as well as 4D-710 for cystic fibrosis lung disease. Additionally, it has promising preclinical development candidates such as 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

The company has established research and collaboration partnerships with leading organizations like uniQure, CRF, Roche, and CFF. Founded in 2013, 4D Molecular Therapeutics Inc. is headquartered in Emeryville, California. To learn more, visit their website at https://www.4dmoleculartherapeutics.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for 4D Molecular Therapeutics Inc (FDMT)

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for 4D Molecular Therapeutics Inc (FDMT)

FDMT Stock Overview

Market Cap in USD 1,378m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-12-11

FDMT Stock Ratings

Growth 5y -2.23
Fundamental -6.79
Dividend -
Rel. Performance vs Sector 3.02
Analysts 4.63/5
Fair Price Momentum 27.56 USD
Fair Price DCF -

FDMT Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

FDMT Growth Ratios

Growth 12m 24.71%
Growth Correlation 12m 17%
Growth Correlation 3m 29%
CAGR 5y -13.62%
Sharpe Ratio 12m 0.18
Alpha vs SP500 12m -18.10
Beta vs SP500 5y weekly 2.11
ValueRay RSI 10.06
Volatility GJR Garch 1y 95.68%
Price / SMA 50 -14.23%
Price / SMA 200 30.28%
Current Volume 417.6k
Average Volume 20d 676.5k

External Links for FDMT Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of FDMT stocks?
As of April 19, 2024, the stock is trading at USD 24.78 with a total of 417,554 shares traded.
Over the past week, the price has changed by -10.54%, over one month by -20.14%, over three months by +45.34% and over the past year by +42.74%.
What is the forecast for FDMT stock price target?
According to ValueRays Forecast Model, FDMT 4D Molecular Therapeutics Inc will be worth about 31.6 in April 2025. The stock is currently trading at 24.78. This means that the stock has a potential upside of +27.56%.
Issuer Forecast Upside
Wallstreet Target Price 52.4 111.6%
Analysts Target Price 35.4 43.0%
ValueRay Target Price 31.6 27.6%